|Bid||4.9600 x 2900|
|Ask||5.0900 x 1100|
|Day's Range||4.8500 - 5.4400|
|52 Week Range||3.6300 - 17.9500|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.00|
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that results from the Company's placebo controlled, randomized, double-blind Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for ALS will be presented as an oral presentation at the 31st International Symposium on ALS/MND to be held as a virtual symposium Dec 9-11th, 2020. In addition, Brainstorm will present the clinical experience with NurOwn outpatient administration during the phase 3 clinical trial in the poster session.
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Trial Does Not Meet Primary Endpoint On November 17, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced topline results from the company’s Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS). The trial did not reach statistical significance for the
Traders are selling off shares of the clinical-stage biotech company following the release of negative top-line results from a phase 3 clinical trial for its leading candidate treatment. BrainStorm Cell Therapeutics has been developing NurOwn as a potential treatment for amyotrophic lateral sclerosis (ALS), a nervous system disease that causes a progressive loss of muscle control and function. With that said, it was generally well-tolerated from a safety standpoint, and did demonstrate some encouraging results; BrainStorm Cell Therapeutics says it has not given up on NurOwn yet.